Compound Radar

AbbVie Inc. (ABBV) Stock Analysis

Price $286.39
Market cap $506.08B
Next earnings Oct 30, 2026
Entry status Watch $222.23–$239.55

Last updated Oct 27, 2026

Published Opportunity

This stock was published as a Compound Radar opportunity on Jul 17, 2026. Performance is tracked publicly from the original signal.

Full track record →
Entry $254.39
Return +12.6%
QQQ +2.4%
Alpha vs QQQ +10.2%

Health Check

Last analyzed Oct 23, 2026

73
73/100 High Quality
  • Financial Health 65
  • Profitability 75
  • Business Quality 100
  • Balance Sheet 55
  • Cash Flow 45

Why this rating?

Health 73/100 — High Quality

Strongest Business Quality 100/100
Softest Cash Flow 45/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

AbbVie Inc. (ABBV) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates AbbVie Inc. 73/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 80.9
  • Forward P/E 17.68
  • PEG 0.58
  • EV/Revenue 8.87

Profitability

  • Revenue Growth 10.2%
  • Gross Margin 72.8%
  • Operating Margin 40.0%
  • Net Margin 9.8%

Financial strength

  • Cash $6.57B
  • Debt $70.88B
  • Net Cash $-64.32B
  • Free Cash Flow $17.82B
  • Current Ratio 0.81

Similar companies

Peers in Drug Manufacturers - General, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - General →

FAQ

How Compound Radar scores and tracks AbbVie Inc. (ABBV).

View Methodology & FAQ →